Cargando…

Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis

BACKGROUND: Moxifloxacin (MOX) is used as a first-choice drug to treat multidrug-resistant tuberculosis (MDR-TB); however, evidence-based dosing optimization should be strengthened by integrative analysis. The primary goal of this study was to evaluate MOX efficacy and toxicity using integrative mod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yun, Hwi-Yeol, Chang, Vincent, Radtke, Kendra K, Wang, Qianwen, Strydom, Natasha, Chang, Min Jung, Savic, Radojka M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825669/ https://www.ncbi.nlm.nih.gov/pubmed/35146045 http://dx.doi.org/10.1093/ofid/ofab660

Ejemplares similares

Increased Moxifloxacin Dosing Among Patients With Multidrug-Resistant Tuberculosis With Low-Level Resistance to Moxifloxacin Did Not Improve Treatment Outcomes in a Tertiary Care Center in Mumbai, India
por: Tornheim, Jeffrey A, et al.
Publicado: (2021)

Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis
por: Solans, Belén P, et al.
Publicado: (2023)

Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes
por: Lee, Jinwoo, et al.
Publicado: (2011)

Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis
por: Fors, John, et al.
Publicado: (2020)

Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model
por: Gupta, U.D., et al.
Publicado: (2015)

Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study
por: Ramirez, Julio, et al.
Publicado: (2021)

Meta-analysis on Effectiveness and Safety of Moxifloxacin in Treatment of Multidrug Resistant Tuberculosis in Adults
por: Guan, Yanmin, et al.
Publicado: (2020)

Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis
por: Mase, Anjeli, et al.
Publicado: (2022)

gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy
por: Murray, Gerald L, et al.
Publicado: (2023)

The role of moxifloxacin in tuberculosis therapy
por: Gillespie, Stephen H.
Publicado: (2016)

A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP)
por: Horcajada, Juan P, et al.
Publicado: (2019)

Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis
por: Sidamo, Temesgen, et al.
Publicado: (2022)

A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis
por: Conde, Marcus B., et al.
Publicado: (2016)

Diabetes Reduces the Rate of Sputum Culture Conversion in Patients With Newly Diagnosed Multidrug-Resistant Tuberculosis
por: Salindri, Argita D., et al.
Publicado: (2016)

Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis
por: Bigelow, Kristina M, et al.
Publicado: (2020)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013
por: Xia, Hui, et al.
Publicado: (2021)

Laboratory-based study of drug resistance and genotypic profile of multidrug-resistant tuberculosis isolates in Salvador, Bahia, Brazil
por: Sousa, Erivelton de Oliveira, et al.
Publicado: (2022)

Analysis of catastrophic costs incurred by patients with multidrug-resistant tuberculosis in an outpatient clinic in the state of Rio de Janeiro
por: de Medeiros, Regielle Luiza, et al.
Publicado: (2023)

Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens
por: Budak, Maral, et al.
Publicado: (2023)

Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies
por: Zhang, Nan, et al.
Publicado: (2020)

Cryptic Resistance Mutations Associated With Misdiagnoses of Multidrug-Resistant Tuberculosis
por: Cancino-Muñoz, Irving, et al.
Publicado: (2019)

Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial
por: Solans, Belén P, et al.
Publicado: (2023)

Xpert MTB/RIF Use Is Associated With Earlier Treatment Initiation and Culture Conversion Among Patients With Sputum Smear-Negative Multidrug-Resistant Tuberculosis
por: Kipiani, Maia, et al.
Publicado: (2021)

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way
por: Deshpande, Devyani, et al.
Publicado: (2016)

Immunomodulatory Agents Combat Multidrug-Resistant Tuberculosis by Improving Antimicrobial Immunity
por: Rao Muvva, Jagadeeswara, et al.
Publicado: (2021)

Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa
por: Loveday, Marian, et al.
Publicado: (2020)

Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization
por: Strydom, Natasha, et al.
Publicado: (2019)

Pulmonary Targeting of Inhalable Moxifloxacin Microspheres for Effective Management of Tuberculosis
por: Vishwa, Bhavya, et al.
Publicado: (2021)

Infectious Diseases (ID) Learning Unit: How Rapidly to Evaluate for Active Tuberculosis Disease in Low-Prevalence Settings
por: Chida, Natasha, et al.
Publicado: (2016)

Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
por: Lodise, Thomas P, et al.
Publicado: (2020)

Toxicities of and inflammatory responses to moxifloxacin, cefuroxime, and vancomycin on retinal vascular cells
por: Miyake, Hitomi, et al.
Publicado: (2019)

Topical moxifloxacin-induced toxic epidermal necrolysis and Stevens-Johnson syndrome
por: Dhavaleshwar, A, et al.
Publicado: (2019)

Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes
por: Lee, Eun Hye, et al.
Publicado: (2019)

Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis
por: Ernest, Jacqueline P., et al.
Publicado: (2021)

The Impact of Multidrug-Resistant Organisms on Outcomes in Patients With Diabetic Foot Infections
por: Henig, Oryan, et al.
Publicado: (2020)

Predicting Risk of Multidrug-Resistant Enterobacterales Infections Among People With HIV
por: Henderson, Heather I, et al.
Publicado: (2022)

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis
por: Imperial, Marjorie Z, et al.
Publicado: (2021)

Moxifloxacin-warfarin interaction
por: Ji, Yan, et al.
Publicado: (2012)

Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach
por: Pienaar, Elsje, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bgo7boo47ifb0o0srmp28uoi66